Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
27 hedge funds and large institutions have $12M invested in Cymabay Therapeutics in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 27 → 27 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
5% less capital invested
Capital invested by funds: $12.7M → $12M (-$637K)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$583K |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$546K |
| 3 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$26.8K |
| 4 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$13.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$7.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$154K |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$88.8K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$33K |
| 4 |
Goldman Sachs
New York
|
-$32K |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$30.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
26
Virtu KCG Holdings
New York
| – | -$33K | -17,208 | Closed |
|
|
27
Goldman Sachs
New York
| – | -$32K | -16,554 | Closed |
|
28
Citadel Advisors
Miami,
Florida
| – | -$25K | -12,692 | Closed |
|
29
Barclays
London,
United Kingdom
| – | -$22K | -11,500 | Closed |
|
30
Bank of America
Charlotte,
North Carolina
| – | -$731 | -414 | -100% |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$1K | -387 | Closed |
|
CBAY Hedge Fund Activity: Q4 2016 in Review
27 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2016, worth a combined $12M — down 5% from $12.7M a quarter earlier.
Fund positioning in CBAY was balanced in Q4 2016: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 7 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $583K. The largest seller was Vanguard Group, cutting an estimated $154K.
- 27 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $12M of Cymabay Therapeutics stock for Q4 2016, down 5% quarter-over-quarter.
- 5 funds opened new Cymabay Therapeutics positions in Q4 2016 and 5 closed out, a net change of 0 holders.
- The largest Cymabay Therapeutics buyer in Q4 2016 was J. Goldman & Co, an estimated $583K added.
- The largest Cymabay Therapeutics seller in Q4 2016 was Vanguard Group, an estimated $154K sold.
Based on aggregated 13F filings for Q4 2016.